



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address : COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APR 30 1992

#36

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fisher's Lane, Room 11-44  
Rockville, MD 20857

Re: Mivacron

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 4,761,418 issued August 2, 1988. The application was filed on March 16, 1992, under Title II of Public Law 98 - 417, the Drug Price Competition and Patent Term Restoration Act of 1984. A Supplemental Declaration was filed on March 20, 1992.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office on the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC § 156 (d) (2) (A).

*C. E. Van Horn*

---

Charles E. Van Horn  
Patent Policy & Programs Administrator  
Office of the Assistant Commissioner for Patents

cc: Dr. L.A. Nielsen  
Burroughs Wellcome Co.  
3030 Cornwallis Road  
Research Triangle Park, NC 27709